Don’t Expect Business As Usual From EMA During Transition, Says BIA Head
BIA CEO Steve Bates says life science companies should not expect business as usual during the EMA’s relocation to Amsterdam, but notes that firms and industry associations are “absolutely aligned” on the need for continued close cooperation between the UK and the EU after Brexit. He also warned that firms may be holding back on investments in clinical trials in the UK.
You may also be interested in...
The chief executives of the APBI and the BIA have told the House of Lords’ Science and Technology Committee that Brexit uncertainty is having an impact on life science investment decisions and that the UK may not be able to benefit from key EU legislative initiatives that it helped to create.
UK proposals for limited cooperation with the EU in medicines regulation, including the recognition of certificates and inspections, are one glimmer of light in an otherwise uncertain post-Brexit regulatory scenario for the UK. But time pressures and political spats over the future relationship could throw the whole enterprise into doubt.
The coronavirus could have serious adverse effects on regulatory procedures at both European Medicines Agency and EU member state level. A new business continuity plan describes how procedures will be prioritized if problems arise.